News

Reducing the levels of the protein NEK2 in the pulmonary arteries lessened disease-driving changes in blood vessels and the heart of a rat model of pulmonary arterial hypertension (PAH) due to congenital heart disease (CHD). The effects were tied to a modulation of the NF-kB pathway involved in vascular…

Synhale Therapeutics has acquired the rights to the experimental therapy telaglenastat (CB-839), which has previously been tested as a potential cancer therapy. The company is planning to launch a Phase 2 clinical trial to test telaglenastat in people with pulmonary hypertension (PH). “This acquisition represents a unique opportunity to…

The first patient has been enrolled in a pivotal study testing the accuracy of Sensydia’s noninvasive Cardiac Performance System (CPS) for measuring cardiovascular function, including pulmonary artery pressure, a key metric used to diagnose and monitor pulmonary hypertension (PH). The multi-center, observational trial (NCT06870591) will compare CPS…

Cereno Scientific has completed a type C meeting with the U.S. Food and Drug Administration (FDA) about the design of a future Phase 2b clinical trial to test CS1, its lead therapy candidate for people with pulmonary arterial hypertension (PAH). Besides defining the trial’s design, the meeting, held…

The Pulmonary Hypertension Association (PHA) has launched a certificate program to provide advanced practice providers and allied health professionals with specialized training for diagnosis, treatment, and management of pulmonary hypertension (PH). Enrollment in the Pulmonary Hypertension Certificate Program’s first group, starting in June, is now open, the PHA…

On May 5, more than 80 organizations around the world will join to raise awareness of pulmonary hypertension (PH), a serious but often under-recognized cardiovascular disease affecting more than 75 million people worldwide. World Pulmonary Hypertension Day, an annual event spearheaded by PHAEurope, also aims to promote…

The PAH Initiative is hosting a video event in May to provide information about the benefits of exercise for people with pulmonary arterial hypertension (PAH). “The Power of Movement: Cardiopulmonary Rehabilitation for PAH” is part of the initiative’s PAH Today national broadcast series. Lana Melendres-Groves, MD, director of…

Heart failure related to pulmonary arterial hypertension (PAH) is becoming more common, with patients living fewer years in full health, a trend that’s predicted to continue, with more cases and deaths expected by 2050, a study showed. In the three decades from 1990 to 2021, women accounted for more…

Pulmonary artery denervation (PADN), a procedure that targets overactive nerves involved in blood vessel constriction, significantly lessens high blood pressure in the lungs of people with pulmonary hypertension (PH), according to a meta-analysis of more than a dozen studies. Pooled data also showed that the approach was associated with…

Treatments approved for pulmonary arterial hypertension (PAH) may reduce by half the risk of serious complications or death in adults and adolescents who also have repaired congenital heart disease (CHD), pooled data analysis of three clinical trials shows. This risk was similarly reduced among the whole PAH patient population…

Corvista Health’s point-of-care device, which can be used to predict pulmonary hypertension in a noninvasive way, also appears to work well at identifying heart failure, accurately detecting patients who have it while ruling it out in others, a study found. Using machine learning to decode data from patients,…

The advocacy organization Phaware is launching a series of podcasts to explore new advances in the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD). The series will be launched as part of “I’m Aware That I’m Rare: the phaware podcast,” which can be found online…